In June 2024, the sixth round of the National High-Value Medical Consumables Centralized Volume-Based Procurement (commonly known as ‘centralized procurement’) officially opened for bidding. This round focuses on high-value medical consumables that are widely used in clinical practice, account for substantial procurement expenditures, and impose heavy financial burdens on patients—such as artificial joints, orthopedic spinal implants, and intraocular lenses. Continuing the core ‘volume-for-price’ mechanism from previous rounds, this procurement leverages the unified national market to achieve economies of scale, significantly lowering prices while ensuring product quality and stable supply. On average, selected products saw price reductions exceeding 50%, with some categories dropping by over 80%. This is expected to save patients and the national health insurance fund tens of billions of RMB annually. Furthermore, the procurement process introduced refined rules—including ‘group-based bidding’ and ‘competitive selection’—to enhance fairness and market competition, while also encouraging participation from innovative domestic manufacturers to support high-quality development in the medical device industry. Overall, the sixth round of centralized procurement not only alleviates patient financial burdens but also promotes efficient allocation of healthcare resources and a healthier industry ecosystem.
2024年6月，第六批国家组织高值医用耗材集中带量采购（简称“集采”）正式开标。本次集采聚焦于临床用量大、采购金额高、群众负担重的高值医用耗材，主要包括人工关节、骨科脊柱类、眼科人工晶体等品类。此次集采延续了前几轮‘以量换价’的核心机制，通过全国统一市场形成规模效应，大幅降低产品价格，同时保障产品质量与供应稳定。据统计，中选产品平均降价幅度超过50%，部分品类降幅甚至达到80%以上，预计将每年为患者和医保基金节省数十亿元支出。此外，本次集采进一步优化了规则设计，如引入‘分组竞价’‘差额中标’等机制，提升公平性与竞争性，并鼓励国产创新产品参与，推动医疗器械产业高质量发展。总体来看，第六批高值医用耗材集采不仅减轻了患者经济负担，也促进了医疗资源的合理配置和行业生态的良性循环。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/14687.html